Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: PH stock price vs REGN: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at REGN's multiple
Needs REGN P/E.
Implied fair value · at PH's multiple
Needs PH P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
17 period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
PARKER-HANNIFIN CORPORATION · implied price per share
Bear
$271.45
Base
$330.29
Bull
$406.93
REGENERON PHARMACEUTICALS, INC. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
HONEYWELL INTERNATIONAL INC
PH vs HON
NORDSON CORP
PH vs NDSN
Eaton Corp plc
PH vs ETN
EMERSON ELECTRIC CO
PH vs EMR
DANAHER CORP /DE/
PH vs DHR
ILLINOIS TOOL WORKS INC
PH vs ITW
AMGEN INC
PH vs AMGN
PFIZER INC
PH vs PFE
BRISTOL MYERS SQUIBB CO
PH vs BMY
BIOGEN INC.
PH vs BIIB
GILEAD SCIENCES, INC.
PH vs GILD
Seagate Technology Holdings plc
PH vs STX
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe PH can sustain its premium valuation through continued ROIC strength and a reacceleration in growth, then hold or avoid adding aggressively; otherwise, the data favors trimming or underweighting PH because it trades far above both REGN-implied and DCF values while not leading REGN on most profitability metrics.
PH trades at a steep premium to REGN on every supplied valuation metric, despite weaker growth and lower profitability on most margin measures. The model-implied price of $427.77 implies 55.6% downside from the current price of $962.89, which is also above both REGN-implied range and the DCF range.
Supporting Metrics
